Your Health, We Care
Release date: 2024-08-15 15:17:12 Recommended: 186
Pemigatinib is a targeted therapy designed for adult patients with advanced, metastatic, or unsuitable surgical resection cholangiocarcinoma who have undergone at least one round of systemic therapy and have been tested to confirm the presence of FGFR2 gene fusions or rearrangements in the body.
These interactions may affect the metabolism, excretion, or efficacy of Pemigatinib, thereby increasing the risk of adverse effects or decreasing the efficacy of treatment.
The metabolism of Pemigatinib is partially dependent on the CYP3A enzyme, and the combination with inducers or inhibitors of the CYP3A enzyme may alter the plasma concentration of Pemigatinib, thereby affecting its efficacy and safety.
CYP3A inducers, such as rifampicin and dexamethasone, may reduce the plasma concentration of Pemigatinib and weaken its efficacy. CYP3A inhibitors, such as clarithromycin and ketoconazole, may increase the plasma concentration of Pemigatinib and increase the risk of toxicity and adverse effects.
Concomitant use with strong or moderate CYP3A inhibitors should be avoided during the use of Pemigatinib, and if this cannot be avoided, the dose of Pemigatinib may need to be adjusted.
During the use of the drug, the following aspects need to be taken to ensure that the treatment is carried out safely and effectively. Patients should pay close attention to their physical condition and medication reactions, and make necessary monitoring and adjustments under the guidance of their doctors.
Patients should avoid high intake of foods and beverages that may affect drug metabolisms, such as grapefruit or grapefruit juice while taking Pemigatinib.
Pemigatinib can cause harm to the fetus or baby and should be avoided by women who are trying to conceive, are pregnant, or are breastfeeding. Patients should be strictly contraceptive while taking the drug and avoid breastfeeding for a period of time after the last dose.
Pemigatinib may interact with other drugs during treatment, and these interactions may affect the efficacy and safety of Pemigatinib. When drug interactions occur, the following measures should be taken:
Patients should inform their doctor as soon as they discover a drug that may interact with Pemigatinib, or if they experience any discomfort while using Pemigatinib. Depending on the patient's specific situation and the risk of drug interactions, the doctor will adjust the medication regimen or take other necessary steps.
Depending on the results of the evaluation, your doctor may adjust the dose, timing, or mode of administration of Pemigatinib to reduce the risk of drug interactions. At the same time, the doctor may also recommend that the patient stop or replace other medications that may interact with Pemigatinib.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
